By hannover-web.com On September 20th, the Shanghai Clinical Innovation and Translation Research Institute, commonly referred to as the “Translation Institute,” was officially launched. This initiative aims to significantly enhance the biopharmaceutical industry and promote innovative clinical research at a high level.
Wang Xingpeng, the director of the Shanghai Shenkang Hospital Development Center, shared insights on the rationale behind the establishment of the Translation Institute. He emphasized its mission to connect clinical innovation with practical application at municipal hospitals, thereby advancing the development of top-tier research hospitals and ensuring that high-quality clinical research outcomes are accessible to more patients.
The institute will concentrate on two primary functions: “promoting result translation” and “providing clinical research services.” Its activities will span three main areas: clinical research and cohort development, technology transfer and investment, as well as artificial intelligence and data mining.
In a prior step, Shanghai unveiled the “Implementation Opinions on Strengthening the City’s Clinical Research System and Capability Building to Support the Development of the Biopharmaceutical Industry.” This document stresses the importance of continuously advancing the translation of clinical research results. It advocates for a market-oriented, professional platform for medical technology result translation aimed at facilitating the high-quality conversion of research findings and explores the establishment of equity holding platforms through investment valuation.
Currently situated in the Zhangjiang Hi-Tech Park of the Pudong New Area, the Translation Institute intends to innovate within the realm of clinical research and disease cohort development. It seeks to create a new service model characterized by foundational support from Shanghai, unique clinical capabilities, corporate participation, and promising growth. Furthermore, it will pursue sustainable development and open-sharing mechanisms, led by government initiatives alongside the involvement of enterprises and municipal hospitals, all underpinned by the Translation Institute.
In terms of technology transfer and investment, the institute aims to consolidate resources for medical innovation, convert scientific achievements into practical applications, incubate hard-tech enterprises, and cultivate the future of the medical industry. It plans to accelerate the creation of a high-quality medical achievement incubation platform that highlights specialized capabilities and makes a significant impact on the industry.
Moreover, the Translation Institute will explore avenues for municipal hospitals regarding intellectual property licensing and equity ownership. It aims to provide comprehensive “companion style” services to fast-track the industrialization of early-stage outcomes and enhance the overall success rate of clinical innovation.
In the realm of artificial intelligence and data mining, the institute will focus on developing medical AI technologies, mining real-world data to support commercial insurance actuarial functions, and constructing multimodal datasets for specific clinical diseases. The goal is to establish platforms for medical big data AI algorithm research, commercial insurance actuarial risk analysis, and real-world medical data services, all aimed at driving the digital and intelligent transformation of Shanghai’s biopharmaceutical sector.
